Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pyramid Schemes and Pipeline Dreams: Adapting to a Tiered Regulatory System for New Drugs

This article was originally published in RPM Report

Executive Summary

FDA's new drug safety authorities suggest that the focus of drug development and lifecycle management strategies need to change. It is no longer a question of what it takes to get approval from FDA, but rather what kind of approval you can get.

You may also be interested in...

Regulatory Alchemy: The Transformative Power of the Opioid REMS

The three-year long process towards a class-wide Risk Evaluation & Mitigation Strategy has been anything but straightforward. Still, the final twist may be the most surprising: FDA is now espousing the most industry-friendly approach on the table. The details of the opioid REMS will take months to work out and years to judge, but understanding the choices made in crafting this policy are a critical starting point.

The Impact of FDAAA On Drug Approvals: Setting the Baseline

An analysis of the first six months of the new era in drug regulation shows that FDA is enthusiastically and creatively applying its new drug safety tools. Biopharma companies will be watching carefully to see how the metrics of the FDAAA era move over time.

Best of the IN VIVO Blog (11/2008)

Best of the Blog is a monthly column highlighting the best of our free online content at In November, Windhover's editorial staff posted 36 articles to the site, covering biopharma, device and diagnostics R&D, business development, regulatory and commercial news. Highlights include : Fundrasing...Forget about it. Exits: Drought is an understatement. But there's new hope for biotech: In starkest terms, the regulatory system, the single biggest stumbling block to pharmaceutical success, is tilting biotech-wards.

Related Content


Related Companies

Related Deals

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts